A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria:

- Participants must satisfy one of the criteria for treatment initiation, as outlined in
the iwCLL NCI-WG guidelines. The criteria include: (a) Evidence of progressive marrow
failure as manifested by the development of, or worsening of, anemia and/or
thrombocytopenia, (b) Massive (i.e., greater than or equal to [>=] 6 centimeters [cm]
below the left costal margin) or progressive or symptomatic splenomegaly, (c) Massive
nodes (i.e., >= 10 cm in longest diameter) or progressive or symptomatic
lymphadenopathy, (d) Progressive lymphocytosis with an increase of greater than (>) 50
percent (%) over a 2-month period or lymphocyte doubling time (LDT) of less than (<) 6
months, (e) Autoimmune anemia and/or thrombocytopenia that is poorly responsive to
corticosteroids or other standard therapy, (f) Constitutional symptoms, defined as any
one or more of the following disease-related symptoms or signs: unintentional weight
loss of >=10% within the previous 6 months, significant fatigue (i.e., Eastern
Cooperative Oncology Group Performance Status [ECOG PS] of 2 or worse or the inability
to work or perform usual activities), fevers higher than 100.5 degrees Fahrenheit
(°F)/38.0 degrees Celsius (°C) for >= 2 weeks without other evidence of infection, or
night sweats for >1 month without evidence of infection

- Absolute neutrophil count (ANC) >=1.5 × 10^9 per liter (/L) and platelets >=75 ×
10^9/L unless cytopenia is caused by the underlying disease, i.e., no evidence of
additional bone marrow dysfunction (e.g., myelodysplastic syndrome, hypoplastic bone
marrow)

- Life expectancy >6 months

- ECOG PS of 0, 1, or 2

- Willing to use acceptable contraceptive measures as defined by the protocol during and
at least for 6 months (male participants) or 12 months (female participants) after the
last dose of study drug

Exclusion Criteria:

- Pregnant or lactating, or intending to become pregnant during the study: Women who are
not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically
sterile must have a negative serum pregnancy test result within 14 days prior to
initiation of study drug

- Participants who have received previous CLL therapy, including investigational
therapies

- Transformation of CLL to aggressive non-Hodgkin's lymphoma (Richter's transformation)

- Inadequate renal function

- Inadequate liver function: National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) Grade 3 liver function tests (aspartate aminotransferase
[AST] or alanine aminotransferase [ALT] >5× upper limit of normal [ULN] for >2 weeks;
bilirubin >3× ULN) unless due to underlying disease

- History of other malignancy, which could affect compliance with the protocol or
interpretation of results

- Participants with active bacterial, viral, or fungal infection requiring systemic
treatment

- Participants with known infection with human immunodeficiency virus (HIV) or human
T-cell leukemia virus 1 (HTLV-1)

- Positive hepatitis serology: (a) Participants with positive serology for hepatitis B,
defined as positivity for hepatitis B surface antigen (HBsAg), or participants who are
HBsAg negative but are hepatitis B core antibody (anti-HBc) positive, (b) Participants
positive for anti-HBc, but with negative hepatitis B Virus (HBV) deoxyribonucleic acid
(DNA), will be considered for inclusion by the Medical Monitor on a case-by-case basis
in order to ensure feasibility of monthly DNA testing and availability of appropriate
care in case of hepatitis B reactivation, (c) Participants with positive serology for
hepatitis C (HCV) unless HCV (by ribonucleic acid [RNA]) is confirmed negative

- History of severe allergic or anaphylactic reactions to monoclonal antibodies

- Evidence of significant, uncontrolled concomitant diseases that could affect
compliance with the protocol or interpretation of results, including significant
cardiovascular disease (such as New York Heart Association Class III or IV cardiac
disease, myocardial infarction within the previous 6 months, unstable arrhythmias, or
unstable angina) or pulmonary disease (including obstructive pulmonary disease and
history of symptomatic bronchospasm)

- Vaccination with a live vaccine a minimum of 30 days prior to study treatment

- Use of investigational agents of any kind within 30 days before study treatment